Pfizer to Buy Rest of Biohaven for $11.6 Billion

Pfizer agree to buy the rest of the Biohaven Pharmaceutical Holding for about $11.6 billion, deploying the cash piled up from the sale of Covid-19 to buy a new migraine drug.

Pfizer said it will pay $148.50 a share in cash for shares of Biohaven it doesn’t already own, nearly 79% more than Monday’s closing price of $83.14 for New Haven, Conn. ., Drug manufacturer. Pfizer to Buy Rest of Biohaven for $11.6 Billion

Edmuns DeMars

Edmund DeMarche is a USTimesPost U.S. News Reporter based in London. His focus is on U.S. politics and the environment. He has covered climate change extensively, as well as healthcare and crime. Edmund DeMarche joined USTimesPost in 2023 from the Daily Express and previously worked for Chemist and Druggist and the Jewish Chronicle. He is a graduate of Cambridge University. Languages: English. You can get in touch with me by emailing

Related Articles

Back to top button